|
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Sicca Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome.
|
24097067 |
2013 |
|
Sjogren's Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome.
|
24097067 |
2013 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
CTD_human |
Quantitative RT-PCR demonstrated that six genes from the combined signatures (CXCL9, ITSN2, GNAI2, H2AFX, INDO, and MGC10986) were significantly differentially expressed in the recurrence versus the non-recurrence group of the 19 cases and the independent breast cancer patient cohort (n = 51) treated with CMF.
|
18925433 |
2009 |
|
Neoplasm Recurrence, Local
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.
|
18925433 |
2009 |
|
Breast Carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Quantitative RT-PCR demonstrated that six genes from the combined signatures (CXCL9, ITSN2, GNAI2, H2AFX, INDO, and MGC10986) were significantly differentially expressed in the recurrence versus the non-recurrence group of the 19 cases and the independent breast cancer patient cohort (n = 51) treated with CMF.
|
18925433 |
2009 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.
|
18925433 |
2009 |
|
Mammary Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.
|
18925433 |
2009 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.
|
18925433 |
2009 |
|
Nephrotic Syndrome
|
0.210 |
Biomarker
|
group |
BEFREE |
Here we show mutations in six different genes (MAGI2, TNS2, DLC1, CDK20, ITSN1, ITSN2) as causing NS in 17 families with partially treatment-sensitive NS (pTSNS).
|
29773874 |
2018 |
|
Nephrotic Syndrome
|
0.210 |
Biomarker
|
group |
MGD |
|
|
|
|
White Blood Cell Count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Asthma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks.
|
29273806 |
2018 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer's disease with OSBPL6, PTPRG, and PDCL3.
|
26830138 |
2016 |
|
EPILEPSY, FOCAL, WITH SPEECH DISORDER AND WITH OR WITHOUT MENTAL RETARDATION
|
0.100 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
|
Personality Disorders
|
0.030 |
Biomarker
|
group |
BEFREE |
Personality and Personality Disorders in Medication-Overuse Headache: A Controlled Study by SWAP-200.
|
31281555 |
2019 |
|
Personality Disorders
|
0.030 |
Biomarker
|
group |
BEFREE |
The Shedler-Westen Assessment Procedure (SWAP-200) was used to assess personality disorders and levels of psychological functioning in a clinical sample (N = 88).
|
28645076 |
2017 |
|
Personality Disorders
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Furthermore, we found that only 16% of our sample presented a personality disorder, while 50% showed a high level of functioning according to the SWAP-200 scales.
|
28210932 |
2017 |
|
Gender Dysphoria
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
The authors review, one by one, the SWAP-200 items related to these areas, and, relying on their clinical experience and on scientific literature on Gender Dysphoria, they propose recommendations for making personality diagnoses meaningful.
|
28238165 |
2017 |
|
Gender Dysphoria
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
Forty-four individuals diagnosed with gender identity disorder (now gender dysphoria), 28 male-to-female and 16 female-to-male, were evaluated using the Shedler-Westen assessment procedure-200 (SWAP-200) to assess personality traits and disorders; the adult attachment interview was used to evaluate their attachment state-of-mind.
|
28210932 |
2017 |
|
Substance Use Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
They showed lower traits of the SWAP-200's cluster A and B disorders than SUD and PD patients, who presented more severe levels of personality impairment.
|
31281555 |
2019 |
|
Bone Cysts, Aneurysmal
|
0.010 |
Biomarker
|
disease |
BEFREE |
RNA sequencing identifies a novel USP9X-USP6 promoter swap gene fusion in a primary aneurysmal bone cyst.
|
30767316 |
2019 |
|
Pathological personality NOS
|
0.010 |
Biomarker
|
disease |
BEFREE |
Eighty-eight MOH patients have been compared with two clinical populations including 99 patients with substance use disorder (SUD) and 91 with PDs using the Shedler-Westen Assessment Procedure-200 (SWAP-200), a clinician-report tool that assesses both normal and pathological personality.
|
31281555 |
2019 |
|
Analgesic Overuse Headache
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Eighty-eight MOH patients have been compared with two clinical populations including 99 patients with substance use disorder (SUD) and 91 with PDs using the Shedler-Westen Assessment Procedure-200 (SWAP-200), a clinician-report tool that assesses both normal and pathological personality.
|
31281555 |
2019 |